Published: June 2022 | Report Code: 12383 | Available Format: PDF
The global particle therapy market size stood at $797.1 million in 2021, which is expected to reach $1,634.4 million by 2030, propelling at a CAGR of 8.3% during 2021–2030. This is mainly ascribed to the high adoption of particle therapy for cancer treatment coupled with the surge in the number of particle therapy centers all over the world.
Moreover, the active involvement of companies to launch particle therapy products also drives the market. For instance, in May 2020, Hitachi Ltd. introduced an advanced proton therapy system in Clinica Universidad de Navarra hospital in Spain. The system is equipped with spot scanning technology having a 360-degree rotating gantry treatment room that effectively delivers the proton beam at the target site.
Proton therapy accounted for more than 90% share in 2021, and the category is projected to witness a higher CAGR, of approximately 8.5%, in the forecast period. This is ascribed to the high adoption of this therapy for treating various cancers, such as pediatric cancer, brain tumor, and breast cancer. As per a government agency, more than 2 million women were diagnosed with breast cancer in 2020 all over the world, making it the most widespread cancer.
Nowadays, proton therapy is employed during all stages of breast cancer treatment, owing to several benefits, such as effective depth-dose distribution and high linear energy distribution (LET) of charged particles, which lead to the formation of DNA lesions, in such a way that it is very difficult for them to repair.
Moreover, hospitals and academics & research centers are focusing on the high adoption of proton therapy equipment in comparison to the heavy-ion therapy equipment, due to the low installation cost of proton therapy equipment, which targets ions directly at the tumor without affecting the normal healthy body cells. In addition, the treatment time in the case of proton therapy is quite less with minimal side effects. Because ions are much heavier than protons, the cost of constructing a heavy-ion therapy center is higher than that of proton therapy. For instance, as per the department of health, the cost of a heavy-ion therapy center is around $200 million, while the cost of a proton therapy center can be as less as $25 million.
Moreover, the total health spending for the treatment of pediatric cancer through the use of proton therapy is less in comparison to radiation therapy. As per a government organization, the average life-span savings per pediatric patient with proton therapy is more than ~$15,000, thereby fueling the particle therapy market growth in this category.
Products, such as cyclotrons, synchrotrons, and synchrocyclotrons, hold more than 80% of the market share, owing to the rising adoption of cyclotrons in various hospitals coupled with various advantages offered by them such as low cost. In addition, the rising inclination toward nuclear scans for diagnosis, and the accessibility of technologically advanced diagnostic devices also drive the market growth in this category.
Additionally, most of the particle therapy facilities, globally, focus on the employment of cyclotrons in comparison to synchrotrons, due to their low cost coupled with small size. For instance, around 60% of European countries utilize cyclotrons for beam production in their proton therapy facilities, 25% use synchrotrons, and around 15% use synchrocyclotrons.
Report Attribute | Details |
Historical Years |
2017-2021 |
Forecast Years |
2022-2030 |
Market Size in 2021 |
$797.1 Million |
Revenue Forecast in 2030 |
$1,634.4 Million |
Growth Rate |
8.3% CAGR |
Report Scope |
Market Trends, Drivers, and Restraints; Revenue Estimation and Forecast; Segmentation Analysis; Regulatory Scenario; Impact of COVID-19; Companies’ Strategic Developments; Market Share Analysis of Key Players; Company Profiling |
Segments Covered |
By Type; By Product & Service; By System; By Cancer Type; By Application; By End User; By Region |
Explore more about this report - Request free sample pages
The single-room systems category is expected to witness a higher CAGR, of around 9%, in the forecast period, due to the low cost per treatment and low development cost of a single-room facility. For instance, as per a government source, the cost of a single-room facility is around $30 million, which is comparatively very high in the case of a multi-room facility that can cost around $100 million.
Pediatric cancer accounted for more than 25% of revenue share in 2021, and the category is projected to record the fastest growth, advancing at a CAGR of around 9.0%, in the forecast period, owing to its high prevalence across the world. Particle therapy is mostly employed in the treatment of pediatric patients due to the high mitosis rate in children, which requires therapy that directly targets the tumor with very few long-term side effects. It provides high precision and radiation control with almost no exposure to normal body cells. For instance, as per a government organization, more than 400,000 cases of pediatric cancers such as brain cancer, leukemia, solid tumor, and lymphomas are witnessed every year, globally.
Report Attribute | Details |
Historical Years |
2017-2021 |
Forecast Years |
2022-2030 |
Market Size in 2021 |
$797.1 Million |
Revenue Forecast in 2030 |
$1,634.4 Million |
Growth Rate |
8.3% CAGR |
Report Scope |
Market Trends, Drivers, and Restraints; Revenue Estimation and Forecast; Segmentation Analysis; Regulatory Scenario; Impact of COVID-19; Companies’ Strategic Developments; Market Share Analysis of Key Players; Company Profiling |
Segments Covered |
By Type; By Product & Service; By System; By Cancer Type; By Application; By End User; By Region |
Explore more about this report - Request free sample pages
The European particle therapy market accounted for the highest revenue in 2021. Additionally, the regional market is expected to register the highest CAGR, of around 9%, in the forecast period, due to the rising number of particle therapy facilities providing clinical operations in the region. For instance, more than 50% of the particle therapy centers are present in Europe, globally. This is because of the favorable government policies and the presence of technologically advanced solutions for disease diagnosis. In addition, the presence of a large number of distribution channels also drives the market growth in the region.
Germany, the U.K., and Spain together hold more than 70% share of the European market. This is attributed to the rising number of cancer cases and the presence of prominent players in these countries. For instance, as per a government source, there were around 700,000 incidents of cancer in Germany in 2020.
North America held the second-largest market share, of around 30%, in 2021, owing to the early adoption of particle therapy treatment coupled with the presence of a large number of hospitals and research institutes in the region. According to the National Association for Proton Therapy, out of 170,000 patients treated with proton therapy globally, more than 70,000 of them were treated in the U.S. alone, in 2021. Also, currently, there are around 41 proton therapy centers in North America, which are intensifying the regional market growth.
Moreover, the recent clearance of various proton therapy solutions in the U.S. by federal organizations also drives the market growth. For instance, in March 2021, the FDA approved the latest proton therapy solution, Monaco, offered by Elekta AB in the U.S. This solution provides a full-featured environment for the delivery of proton therapy.
In recent years, players in the market have been involved in product launches and partnerships, in order to attain a significant position. For instance, in March 2022, IBA Worldwide and Tractebel Group announced their partnership to support the proton therapy business of the former.
The study offers a comprehensive market segmentation analysis along with market estimation for the period 2017-2030.
Based on Type
Based on Product & Service
Based on System
Based on Cancer Type
Based on Application
Based on End User
Geographical Analysis
The particle therapy market size stood at $797.1 million in 2021.
During 2021–2030, the growth rate of the particle therapy market will be 8.3%.
Hospitals are larger end users of particle therapy.
The major drivers of the particle therapy market include the rising incidences of cancer and the promulgating number of particle therapy centers for cancer treatment across the globe.
Get a bespoke market intelligence solution
Want a report tailored exactly to your business strategy?
Request CustomizationWant an insight-rich discussion with the report author?
Speak to AnalystOur dedication to providing the most-accurate market information has earned us verification by Dun & Bradstreet (D&B). We strive for quality checking of the highest level to enable data-driven decision making for you
Our insights into the minutest levels of the markets, including the latest trends and competitive landscape, give you all the answers you need to take your business to new heights
With 24/7 research support, we ensure that the wheels of your business never stop turning. Don’t let time stand in your way. Get all your queries answered with a simple phone call or email, as and when required
We take a cautious approach to protecting your personal and confidential information. Trust is the strongest bond that connects us and our clients, and trust we build by complying with all international and domestic data protection and privacy laws